Winning CGM Tenders: A Practical Guide to Local Content and Public Procurement

Public procurement moves a large share of the world's CGM volume — national diabetes programs, hospital chains, insurer formularies, employer health schemes. And across 2025–2026, one line has been appearing in more and more of those tender documents: local value-add required.

That single line quietly disqualifies every importer who assumed a container of finished devices was a strategy. This article explains what CGM tenders actually score, how SKD assembly changes your eligibility, and what to prepare a year before the bid opens.

Verid Bio was the first CGM provider to enable SKD/CKD production models overseas — largely because our partners kept asking how to qualify for tenders that finished-goods importers could no longer win.

What a CGM tender actually scores

Tender scoring varies by country, but the scorecard shape is remarkably consistent:

Criterion	Typical weight	Who wins it
Compliance & registration	Gate, not points	Anyone without it scores zero — no partial credit
Technical specification	High	Manufacturers and brands whose spec was written for the tender
Price	High, but rarely decisive alone	Aggressive bidders with thin service plans lose here over time
Local content / value-add	Rising, often decisive	Local assemblers and true local manufacturers
Supply reliability & track record	Medium	Brands with documented delivery history
After-sales, training, service	Medium	Distributors with real clinical support teams

The pattern that surprises first-time bidders: compliance is binary. A missing ISO 13485 certificate or an expired local registration is not a scoring penalty — it is a disqualification before your price is ever opened.

The local-content shift

Two forces are rewriting CGM tender rules:

1. Industrial policy. Governments increasingly treat medical devices as strategic manufacturing, and score bids on jobs, local assembly and technology transfer — not just landed price.
2. Supply security. Post-2020, procurement officers remember what import delays did to chronic-care programs. Local assembly capability reads as risk reduction.

For a CGM program, the practical ladder of local value-add looks like this:

• Finished-goods import — zero local content. Increasingly ineligible for national tenders.
• Final assembly & packaging in-country (SKD) — the minimum configuration most local-content rules recognize. Kits arrive complete; your facility assembles, packages and releases the product under the manufacturer's process documentation.
• Deep localization (CKD) — component-level production with substantial local value-add. Wins the maximum scoring tier and the strongest tariff position.

If tenders are in your 24-month plan, CGM SKD is usually the entry configuration, and our manufacturing models comparison shows how SKD and CKD sit against private label and OEM.

Twelve months before the bid: your preparation list

Tender losses are usually baked in a year earlier. The checklist:

Regulatory (months 1–6, longest lead time) - Local registration or recognition of the manufacturer's approval, with your entity as the license holder where required - ISO 13485 certificate from the manufacturer — current, in force, scope covering CGM - Free Sale Certificate / Certificate to Foreign Government as required - Local language labeling and IFU approved

Operational (months 4–9) - SKD line qualified, with process documentation and release criteria transferred from the factory - QC capability demonstrated: documented inspection, calibration records, trained staff - Warehousing and cold-chain-safe storage as applicable - A track record — even a small private-channel contract — because "no delivery history" is the quiet killer in scoring

Commercial (months 6–12) - Registered bid entity, local tax and import compliance in order - References: clinical sites, pilot programs, existing distribution - Service plan: training for nurses and pharmacists, hotline, complaint handling — procurement reads this section seriously - Pricing built on your real landed + assembly cost structure, not the factory's ex-works quote

If you are choosing the manufacturing partner this whole plan depends on, the due-diligence questions are in how to choose a CGM SKD manufacturer.

The three mistakes that lose winnable tenders

1. Bidding import-only against local-content scoring. No price is low enough to beat a zero on a weighted local-value criterion. If the tender scores local content, your only real decision is which localization depth to commit to — the bid itself is theater.

2. Treating the SKD line as a checkbox. Procurement officers increasingly audit. A line that exists on paper and fails inspection does not just lose this tender; it poisons your entity's record for the next cycle. Build the quality system as if an inspector is already booked.

3. Ignoring the after-sales score. The cheapest bid with a one-line service plan loses to a mid-price bid with named trainers, a hotline SLA and documented training materials. This is also the section where a genuine local partner outranks the global brand that treats your market as a shipping destination.

The regional reality

The direction of travel is unmistakable: procurement across emerging CGM markets is rewarding local assembly and penalizing pure import. We covered the underlying shift in the regional era of CGM — the markets that will grow fastest through 2030 are the ones where suppliers invest in local capability rather than shipping volume.

If you are deciding between building a tender-ready manufacturing operation and the lighter distribution route first, becoming a CGM distributor compares the two paths — and they are not mutually exclusive; many winning programs start as distribution and graduate into SKD once the tender pipeline justifies the line.

Talk to us: contact@verid.bio — we can walk through your target market's tender structure and tell you which localization depth is realistic before you spend a year preparing the wrong bid.